Actively Recruiting
Testing IL-17a Levels to Guide Treatment in Adults with Active Axial Spondyloarthritis After NSAID Failure
Led by Centre Hospitalier Universitaire de Nice · Updated on 2022-10-24
50
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating spondyloarthritis SpA, a condition causing joint inflammation, to better understand how to choose the best biological treatment for patients with active disease. Currently, no validated biomarkers or direct comparison studies exist to guide the choice between different biologic agents like TNF inhibitors and IL-17 inhibitors. This study aims to assess whether measuring certain immune proteins, specifically IL-17, after stimulating immune cells can help predict how well patients respond to biological treatment. Participants in this observational study will have blood samples taken to measure IL-17 levels following lymphocyte stimulation. The study involves patients with active SpA who require biological treatment after failing at least two non-steroidal anti-inflammatory drugs NSAIDs. The primary goal is to demonstrate that this cytokine test is feasible, and secondly, to determine if IL-17 levels can predict treatment response three months after starting biological therapy. During the 18-month study period, researchers will collect and analyze blood samples to perform the IL-17 assay. They will monitor patient disease activity and treatment outcomes to understand the relationship between cytokine levels and therapeutic response. This approach aims to provide a useful tool to support personalized treatment decisions in active SpA, improving how biological therapies are chosen and managed.
CONDITIONS
Brief Title
IL17 Rate and Spondyloarthritis
Research Team
C
Christian ROUX
B
Barbara SEITZ-POLSKI
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here